![](/wp-content/uploads/2018/10/almZ0XTeQpa1lklBa3Z0.png)
$599
Novartis Q4 ’17 Earnings Update
Novartis hosted its Q4 and full year 2017 earnings updates. Novartis briefly discussed its SGLT1/2i (LIK066), which is being developed for obesity. Of note, Novartis said it anticipates completing their Ph2b trial in H2 ’18 with Ph3 to potentially initiate as early as YE ’18 or early 2019. Below are highlights from the calls.